ScholarIQanswers from OpenAlex

Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy

PaperCitations, authors & open-access status

Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy have?

ScholarIQcitation count

Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy has 316 citations in the OpenAlex counts ScholarIQ stores.

When was Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy published?

ScholarIQyear

Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy has 1996 year in the ScholarIQ index.

What is the open-access status of Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy?

ScholarIQoa status

Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy has green oa status in the ScholarIQ index.

What is the DOI of Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy?

ScholarIQdoi

The DOI for Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy is on the source record.

What is the PMID of Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy?

ScholarIQpmid

The PMID for Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy is on the source record.

What is the OpenAlex record for Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy?

ScholarIQopenalex

The OpenAlex for Nonpeptide Angiotensin II Receptor Antagonists:  The Next Generation in Antihypertensive Therapy is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial